Igenica Inc, the biopharmaceutical firm dedicated to developing antibodies and antibody-drug conjugates to treat the Big C, obtained $14 million in its Series C extension round.
Series C extension
Breaking News
Igenica Inc, the biopharmaceutical firm dedicated to developing antibodies and antibody-drug conjugates to treat the Big C, obtained $14 million in its Series C extension round.